Publication of unaudited financial results for the quarter and half year ended September 30, 2025.
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech has published its unaudited financial results for Q2 FY26 (ended September 30, 2025) in Business Standard and Sakal on November 12, 2025, as required by SEBI listing rules. On a consolidated basis, Q2 revenue stood at Rs. 135.66 crore versus Rs. 97.91 crore in Q2 FY25, a rise of about 39%. Consolidated net profit for the quarter came in at Rs. 18.03 crore, up sharply from Rs. 11.12 crore a year earlier. For the half year, consolidated revenue grew to Rs. 280.69 crore from Rs. 178.86 crore, while net profit jumped to Rs. 39.63 crore from Rs. 5.19 crore. On a standalone basis, Q2 revenue was Rs. 112.64 crore and net profit Rs. 14.72 crore. EPS (consolidated, basic) for Q2 stood at Rs. 6.48 versus Rs. 3.94 in the year-ago quarter.
The numbers reflect strong year-on-year growth in both revenue and profitability, especially at the consolidated level, which is positive for shareholders. However, sequential performance dipped compared to Q1 FY26, so investors may focus on whether margins can be sustained. The filing itself is a routine regulatory disclosure and is unlikely to move the stock on its own.